Quest Diagnostics Inc. (NYSE:DGX) will continue to aggressively buy back shares of its own stock in 2010, after its board authorized another $750 million stock repurchasing plan on top of the more than 10 million shares it bought back last year.
MassDevice Earnings Roundup
GE Healthcare continues to recover from a sharp drop in hospital spending earlier in 2009, posting its best numbers of the year during the fourth quarter, but still trailed year-over-year comparisons during the three months ended Dec. 31.
The medical-equipment manufacturing unit at General Electric Co. (NYSE:GE) generated $4.7 billion in revenues during the quarter, up nearly $900 million from the previous three-month period. Segment profit topped the previous quarter by $403 million, or 79.3 percent, climbing from $508 million during the quarter ended Sept. 30, 2009, to $911 million over the final three months of the year.
Urologix Inc. (NSDQ:ULGX) posted second-quarter sales of $4.1 million for the three months ended Dec. 31, 2009, up 20 percent compared with $3.4 million during the same period in 2008. Urologix posted a net loss of $273,000 for the quarter, compared with a net loss of $1.1 million during Q2 2008:
Solos Endoscopy Inc. (OTC:SNDY) reported $125,791 in fourth-quarter sales, a 9.2 percent uptick compared with its third-quarter sales.
The Boston-based company, which makes endoscopic instruments and imaging equipment, said the increase over the $115,159 worth of sales transactions it posted during Q3 2009 was consistent with its full-year results.
Somanetics Corp. (NSDQ:SMTS) posted fourth-quarter sales of $14.5 million for the three months ended Nov. 30, 2009, up 6.3 percent compared with $13.7 million during the same period during fiscal 2008. Net income fell 54.5 percent to $1.5 million, compared with $3.3 million during Q4 2008:
Meridian Bioscience Inc. posted first-quarter sales of $42.5 million for the three months ended Dec. 31, 2009, up 23.8 percent compared with $34.3 million during the same period in fiscal 2009. Net earnings rose 10.5 percent to $8.9 million, compared with $8.1 million during Q1 2009:
CINCINNATI–(BUSINESS WIRE)–Meridian Bioscience, Inc. (NASDAQ: VIVO):
Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today:
An 18 percent uptick in revenues from its medical devices segment drove a 7.2 percent sales boost for Covidien plc (NYSE:COV) during the first quarter of fiscal 2010, despite increases in sales, marketing and research & development spending.
The Mansfield, Mass.-based medical device monolith posted sales of $2.75 billion during the three months ended Dec. 25, 2009, compared with $2.56 billion during the same period last year. Net income for the quarter rose to $412 million (82 cents per diluted share), up 6.7 percent compared with $386 million (76 cents per diluted share) during the three months ended Dec. 26, 2008.
Osteotech Inc. (NSDQ:OSTE) posted preliminary fourth-quarter sales of $26.3 million and preliminary revenues of $96.7 million for 2009:
Caliper Life Sciences Inc. (NSDQ:CALP) said it expects to beat its own expectations for the fourth quarter’s top line, reporting preliminary revenues of $37.6 million for the three months ended Dec. 31, 2009.
The Hopkinton, Mass.-based lab equipment and services provider credited stronger-than-expected sales of its Ivis and LabChip instruments for the boon, along with license revenues from the deal it announced last week with Becton, Dickinson & Co. (NYSE:BDX). Caliper had predicted sales of between $33 million and $35 million for the quarter.
Bruker Corp. (NSDQ:BRKR) likely generated more than $340 million in revenues during the fourth quarter, beating both year-ago levels and consensus analyst opinion for the period, according to company officials.
The preliminary revenue figures for the three months ended Dec. 31, 2009, were reported Jan. 13 as part of an investor presentation by Bruker executives at the J.P. Morgan Healthcare Conference in San Francisco. During their prepared remarks, CEO Frank Laukien and chief accounting officer Brian Monahan said the firm finished 2009 with a “healthy” order backlog and is beginning to see a gradual recovery in industrial orders.
PLYMOUTH, Minnesota — Cardiology device maker ATS Medical Inc.‘s (NSDQ:ATSI) stock plummeted 18 percent in early afternoon trading Jan. 12, a day after the company announced it expects losses for the fourth quarter and full year of 2009.
The company blamed the worse-than-expected projections on slow growth in its heart valve and heart surgery businesses, according to a statement. Its share price had fallen to $2.65 early Tuesday afternoon, after closing the prior day at $3.24.